Thyroid disorder — all decisions

The Board denied service connection for hypothyroidism, GERD, and bruxism. The Veteran's PTSD was not granted an earlier effective date prior to December 28, 2020, or a higher rating before April 23, 2021. The back disability claim was also denied.

The Board granted service connection for hypertension and hypothyroidism, both due to presumed exposure to herbicide agents under the PACT Act. Other claims were either dismissed or remanded for further evidence.

The Board denied an initial compensable rating for hypothyroidism.

The Board granted a 60 percent disability rating for xerosis with dry skin due to hypothyroidism, effective August 10, 2022, but denied an initial compensable disability rating for hypothyroidism and remanded claims for service connection for gastroesophageal reflux disease (GERD) and hypertension.

The Board denied service connection for sleep apnea, hypothyroidism, and muscle injury with pain as the evidence did not support a finding that these conditions began during active military service or are otherwise related to an in-service injury, event, or disease.

The Board granted restoration of a separate evaluation of 10 percent for fatiguability as a residual of hypothyroidism beginning September 22, 2022, but remanded the other issues.

The Board denied the Veteran's claim for an earlier effective date for service connection for hypothyroidism based on clear and unmistakable error in a September 2014 rating decision.

The Board dismissed the appeal for service connection for tinnitus and denied an initial compensable rating for hypothyroidism.

The appeal for a higher rating for hypothyroidism is remanded.

The Board denied a compensable disability rating for the service-connected hypothyroidism as there was no evidence of myxedema or other compensable residual signs or symptoms.

The Board denied service connection for chronic obstructive pulmonary disease, thyroid cancer, and diabetes mellitus type II as the evidence did not support a causal relationship between these conditions and the Veteran's military service or any toxic exposures.

The Board remands the claim for a thyroid disorder to provide the Veteran with a VA examination as instructed in the October 2024 Remand.

The Board granted service connection for erectile dysfunction as secondary to hypertension and assigned a 20 percent rating for bilateral hearing loss from May 11, 2023, through August 9, 2024.

The Board granted a disability rating of 30 percent, but no higher, for the Veteran's service-connected hypothyroidism.

The Board granted an 80 percent disability rating for seizure disorder, a 30 percent rating for left eye atrophy and blindness, and a TDIU due to the seizure disorder. The discontinuation of the 100 percent disability rating for Rosai-Dorfman disease was upheld.

The Board denied initial compensable ratings for testicular atrophy with male sterility and hypogonadism, deviated septum, migraines, and hypothyroidism. A 100 percent rating was granted for Meniere's syndrome.

The Board denied service connection for osteoporosis and remanded the claim for further development regarding hypothyroidism.

The Board denied a compensable rating for papillary thyroid carcinoma and nasopharyngeal carcinoma, but granted service connection for vocal cord paralysis and odynophagia as additional residual disabilities due to the service-connected nasopharyngeal carcinoma.

The Board remands the appeal for further development, specifically to obtain VA treatment records from the CBOC in Charlotte Hall, Maryland.

The Board remands the appeal regarding an earlier effective date of service connection for thyroid toxicosis/hypothyroidism due to a pre-decisional error in fulfilling statutory and regulatory duties.